ADC Therapeutics (ADCT) Gains from Investment Securities (2023 - 2026)

ADC Therapeutics (ADCT) has reported Gains from Investment Securities for 3 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.

• Quarterly Gains from Investment Securities changed N/A year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 million (down 303.56% YoY) and the FY2024 annual result came in at -$296000.0, up 40.44% from the prior year.
• Gains from Investment Securities eased to -$2.2 million in Q1 2026 per ADCT's latest filing, from -$4000.0 in the prior quarter.
• Over the last five years, Gains from Investment Securities for ADCT reached as high as $3.1 million in Q1 2024 and fell as low as -$2.2 million in Q1 2026.
• A 3-year average of $160000.0 and a median of -$20000.0 in 2023 frame the typical range for Gains from Investment Securities.
• The largest YoY upside for Gains from Investment Securities was 11250.0% in 2024 against a maximum downside of 707.14% in 2024.
• Year by year, Gains from Investment Securities stood at $279000.0 in 2023, then tumbled by 101.43% to -$4000.0 in 2024, then tumbled by 55575.0% to -$2.2 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$2.2 million, -$4000.0, and -$1.1 million for Q1 2026, Q4 2024, and Q3 2024 respectively.